JP2020523029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523029A5 JP2020523029A5 JP2019569397A JP2019569397A JP2020523029A5 JP 2020523029 A5 JP2020523029 A5 JP 2020523029A5 JP 2019569397 A JP2019569397 A JP 2019569397A JP 2019569397 A JP2019569397 A JP 2019569397A JP 2020523029 A5 JP2020523029 A5 JP 2020523029A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cancer
- hue71
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 6
- 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims 6
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- -1 chromogens Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000483002 Euproctis similis Species 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 claims 1
- 206010001323 adrenal adenoma Diseases 0.000 claims 1
- 208000015234 adrenal cortex adenoma Diseases 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 208000001969 capillary hemangioma Diseases 0.000 claims 1
- 239000001390 capsicum minimum Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000010893 malignant breast melanoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 208000010485 smooth muscle tumor Diseases 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001913 submandibular gland Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520382P | 2017-06-15 | 2017-06-15 | |
| US62/520,382 | 2017-06-15 | ||
| PCT/US2018/037645 WO2018232188A1 (en) | 2017-06-15 | 2018-06-14 | Anti-l1-cam antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523029A JP2020523029A (ja) | 2020-08-06 |
| JP2020523029A5 true JP2020523029A5 (enExample) | 2021-07-26 |
| JP7353187B2 JP7353187B2 (ja) | 2023-10-05 |
Family
ID=64660699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569397A Active JP7353187B2 (ja) | 2017-06-15 | 2018-06-14 | 抗ｌ１－ｃａｍ抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11597764B2 (enExample) |
| EP (1) | EP3638299A4 (enExample) |
| JP (1) | JP7353187B2 (enExample) |
| CN (2) | CN111093693B (enExample) |
| CA (1) | CA3067351A1 (enExample) |
| IL (1) | IL271398A (enExample) |
| WO (1) | WO2018232188A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271462A1 (en) | 2013-03-13 | 2014-09-18 | Imaginab, Inc. | Antigen binding constructs to cd8 |
| CN115960230A (zh) | 2015-08-07 | 2023-04-14 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN111093693B (zh) * | 2017-06-15 | 2024-08-09 | 纪念斯隆-凯特林癌症中心 | 抗l1-cam抗体及其用途 |
| US11884729B2 (en) | 2018-06-29 | 2024-01-30 | ApitBio, Inc | Anti-L1CAM antibodies and uses thereof |
| CA3133074A1 (en) * | 2019-03-11 | 2020-09-17 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| US20220177579A1 (en) * | 2019-04-08 | 2022-06-09 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| CN114558122B (zh) * | 2022-04-27 | 2023-02-21 | 北京肿瘤医院(北京大学肿瘤医院) | 放射核素标记的过氧化氢酶及其应用 |
| CN120019074A (zh) * | 2022-09-21 | 2025-05-16 | 艾尔瑟拉股份有限公司 | 与l1cam结合的新型结合分子 |
| IL320220A (en) | 2022-11-09 | 2025-06-01 | Cis Biopharma Ag | Antibodies against L1-CAM and their uses for diagnostic and therapeutic applications |
| WO2025238187A1 (en) | 2024-05-15 | 2025-11-20 | Cis Biopharma Ag | Immunoconjugates targeting l1-cam |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107045A (en) * | 1994-06-30 | 2000-08-22 | Oklahoma Medical Research Foundation | Antibodies to lipoproteins and apolipoproteins and methods of use thereof |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| WO2007114550A1 (en) * | 2006-04-03 | 2007-10-11 | Korea Research Institute Of Bioscience And Biotechnology | A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same |
| WO2007143098A2 (en) * | 2006-06-02 | 2007-12-13 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (hgf) binding proteins |
| CN101528258A (zh) * | 2006-08-23 | 2009-09-09 | 韩国生命工学研究院 | 治疗肺癌的药物组合物，抑制肺癌生长或侵入的方法和治疗肺癌的方法 |
| AU2008201871A1 (en) | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| KR101501736B1 (ko) | 2008-12-05 | 2015-03-12 | 한국생명공학연구원 | 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용 |
| ES2734886T3 (es) * | 2009-11-24 | 2019-12-12 | Alethia Biotherapeutics Inc | Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral |
| AU2011333738A1 (en) | 2010-11-24 | 2013-07-11 | Glaxo Group Limited | Multispecific antigen binding proteins targeting HGF |
| KR20160044598A (ko) * | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
| WO2014077648A1 (ko) * | 2012-11-16 | 2014-05-22 | 강원대학교산학협력단 | 인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도 |
| CN105849120A (zh) * | 2013-10-06 | 2016-08-10 | 美国卫生和人力服务部 | 修饰的假单胞菌外毒素a |
| CN111093693B (zh) * | 2017-06-15 | 2024-08-09 | 纪念斯隆-凯特林癌症中心 | 抗l1-cam抗体及其用途 |
-
2018
- 2018-06-14 CN CN201880052266.7A patent/CN111093693B/zh active Active
- 2018-06-14 JP JP2019569397A patent/JP7353187B2/ja active Active
- 2018-06-14 CA CA3067351A patent/CA3067351A1/en active Pending
- 2018-06-14 EP EP18818419.6A patent/EP3638299A4/en active Pending
- 2018-06-14 WO PCT/US2018/037645 patent/WO2018232188A1/en not_active Ceased
- 2018-06-14 CN CN202411020658.9A patent/CN119161477A/zh active Pending
- 2018-06-14 US US16/622,274 patent/US11597764B2/en active Active
-
2019
- 2019-12-12 IL IL271398A patent/IL271398A/en unknown
-
2023
- 2023-03-06 US US18/179,159 patent/US12486323B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523029A5 (enExample) | ||
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| Paul et al. | Cancer therapy with antibodies | |
| Barzaman et al. | Breast cancer immunotherapy: Current and novel approaches | |
| Herrera et al. | Bispecific antibodies: advancing precision oncology | |
| JP2021531764A5 (enExample) | ||
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| JP2020103301A5 (enExample) | ||
| JP2020534017A5 (enExample) | ||
| Lutterbuese et al. | Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA | |
| JP2020534250A5 (enExample) | ||
| FI3802608T3 (fi) | Cd3-vasta-aineita ja niiden käyttötapoja | |
| JP2020501531A5 (enExample) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2020512281A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| US20240197931A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| JP2005538701A5 (enExample) | ||
| JP2020507571A5 (enExample) | ||
| Luo et al. | Design and applications of bispecific heterodimers: molecular imaging and beyond | |
| CN104211814A (zh) | 用于消耗靶膜蛋白的组合物 | |
| JP2018501211A5 (enExample) | ||
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| Lan et al. | Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview |